Medical Editor: John P. Cunha, DO, FACOEP Last updated on RxList: 1/13/2022

Drug Summary

What Is VisionBlue?

VisionBlue (trypan blue) Ophthalmic Solution is a selective tissue staining agent used as an aid in ophthalmic surgery by staining the anterior capsule of the lens.

What Are Side Effects of VisionBlue?

Common side effects of VisionBlue include:

  • temporary blue coloration of the eye, and
  • staining of implanted lenses.

Dosage for VisionBlue

VisionBlue is packaged in a 2.25 mL dose syringe to which a blunt cannula has to be attached.

What Drugs, Substances, or Supplements Interact with VisionBlue?

VisionBlue may interact with other drugs. Tell your doctor all medications and supplements you use.

VisionBlue During Pregnancy or Breastfeeding

During pregnancy, VisionBlue should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Additional Information

Our VisionBlue (trypan blue) Ophthalmic Solution Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

Drug Description


VisionBlue® (trypan blue ophthalmic solution) 0.06% is a sterile solution of trypan blue (an acid di-azo group dye). VisionBlue® (trypan blue) is a selective tissue staining agent for use as a medical aid in ophthalmic surgery.

Each mL of VisionBlue® 0.06% contains: 0.6 mg trypan blue; 1.9 mg sodium mono-hydrogen orthophosphate (Na2HPO4.2H2O); 0.3 mg sodium di-hydrogen orthophosphate (NaH2PO4•2H2O); 8.2 mg sodium chloride (NaCl); and water for injection. The pH is 7.3 - 7.6. The osmolality is 257-314 mOsm/kg.

The drug substance trypan blue has the chemical name 3,3'-[(3,3'-dimethyl-4,4'-biphenylylene) bis (azo)] bis(5-amino-4-hydroxy-2,7-naphthalenedisulfonic acid) tetra sodium salt, a molecular weight of 960.8, a molecular formula of C34H24N6Na4O14S4, and has the following chemical structure:

 VisionBlue® (trypan blue) Structural Formula Illustration

Indications & Dosage


VisionBlue® (trypan blue) is indicated for use as an aid in ophthalmic surgery by staining the anterior capsule of the lens.


Cataract surgery

VisionBlue® (trypan blue) is packaged in a 2.25 mL syringe to which a blunt cannula has to be attached.

After opening the eye, an air bubble is injected into the anterior chamber of the eye in order to minimize dilution of VisionBlue® (trypan blue) by the aqueous. VisionBlue® (trypan blue) is carefully applied onto the anterior lens capsule using a blunt cannula. Sufficient staining is achieved as soon as the dye has contacted the capsule. The anterior chamber is then irrigated with balanced salt solution to remove all excess dye. An anterior capsulotomy can then be performed.


VisionBlue® (trypan blue) 0.06% is supplied as follows:

0.5 mL of VisionBlue® (trypan blue) in a sterile single-use Luer Lok, 2.25 mL glass syringe, grey rubber plunger stopper and tip cap with polypropylene plunger rod in a peel pouch.


VisionBlue® (trypan blue) is stored at 15-25°C (59-77°F). Protect from direct sunlight.

Manufactured by : D.O.R.C. International b.v., Scheijdelveweg 2, 3214 VN Zuidland, The Netherlands. Distributed in the United States by : Dutch Ophthalmic USA, One Little River Road, P.O. Box 968, Kingston, NH-03848, U.S.A. Phone: 800-75-DUTCH or 603-642-8468.

Side Effects & Drug Interactions


Adverse reactions reported following use of VisionBlue® (trypan blue) include discoloration of high water content hydrogen intraocular lenses (see CONTRAINDICATIONS) and inadvertent staining of the posterior lens capsule and vitreous face. Staining of the posterior lens capsule or staining of the vitreous face is generally self limited, lasting up to one week.


No information provided.

Warnings & Precautions


No information provided.


General: It is recommended that after injection all excess VisionBlue® (trypan blue) be immediately removed from the eye by thorough irrigation of the anterior chamber.

Carcinogenesis, mutagenesis, impairment of fertility

Trypan blue is carcinogenic in rats. Wister/Lewis rats developed lymphomas after receiving subcutaneous injections of 1% trypan blue dosed at 50 mg/kg every other week for 52 weeks (total dose approximately 1,250,000-fold the maximum recommended human dose of 0.06 mg per injection in a 60 kg person, assuming total absorption).

Trypan blue was mutagenic in the Ames test and caused DNA strand breaks in vitro.


Teratogenic Effects

Pregnancy Category C.

Trypan blue is teratogenic in rats, mice, rabbits, hamsters, dogs, guinea pigs, pigs, and chickens. The majority of teratogenicity studies performed involve intravenous, intraperitoneal, or subcutaneous administration in the rat. The teratogenic dose is 50 mg/kg as a single dose or 25 mg/kg/day during embryogenesis in the rat. These doses are approximately 50,000- and 25,000-fold the maximum recommended human dose of 0.06 mg per injection based in a 60 kg person, assuming that the whole dose is completely absorbed. Characteristic anomalies included neural tube, cardiovascular, vertebral, tail, and eye defects. Trypan blue also caused an increase in post-implantation mortality, and decreased fetal weight. In the monkey, trypan blue caused abortions with single or two daily doses of 50 mg/kg between 20th to 25th days of pregnancy, but no apparent increase in birth defects (approximately 50,000-fold maximum recommended human dose of 0.06 mg per injection, assuming total absorption). There are no adequate and well-controlled studies in pregnant women. Trypan blue should be given to a pregnant woman only if the potential benefit justifies the potential risk to the fetus.

Nursing mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when trypan blue is administered to a nursing woman.

Pediatric use

The safety and effectiveness of trypan blue have been established in pediatric patients. Use of trypan blue is supported by evidence from an adequate and well-controlled study in pediatric patients.

Geriatric use

No overall differences in safety and effectiveness have been observed between elderly and younger patients.

Overdose & Contraindications


No information provided.


VisionBlue® (trypan blue) is contraindicated when a non-hydrated (dry state), hydrophilic acrylic intraocular lens (IOL) is planned to be inserted into the eye because the dye may be absorbed by the IOL and stain the IOL.

Clinical Pharmacology


VisionBlue® (trypan blue) selectively stains connective tissue structures in the human eye such as the anterior lens capsule of the human crystalline lens.

VisionBlue® (trypan blue) is intended to be applied directly on the anterior lens capsule, staining any portion of the capsule which comes in contact with the dye. Excess dye is washed out of the anterior chamber. The dye does not penetrate the capsule, permitting visualization of the anterior capsule in contrast to the non-stained lens cortex and inner lens material.

Medication Guide


No information provided. Please refer to the PRECAUTIONS section.

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.